title: [Effects of fasudil on bleomycin-induced pulmonary fibrosis in mice and on the biological behaviors in NIH3T3 mouse fibroblast cell line].
abstract: OBJECTIVE
  To determine the beneficial effects and mechanisms of fasudil, a selective ROCK inhibitor, on bleomycin-induced pulmonary fibrosis in mice and to determine the effects and mechanisms of fasudil on the biological behaviors in NIH3T3 mouse fibroblast cell line.
  
  
  METHODS
  The BPF model was induced by a single dosage of 2.5 mg/kg bleomycin intratracheal injection in mice and fasudil intraperitoneal injection was given to the mice. The fibrosis degree was determined pathologically by using the Ashcroft scoring method and biochemically by hydroxyproline assay in lung tissue. NIH3T3 mouse fibroblast cell line was cultured in vitro and fasudil was given to the cell. The proliferation activity in NIH3T3 cells were detected by MTT assay and flat colony forming experiment. The migration activity in NIH3T3 cells were detected by scratch test and transwell chamber experiment. The expression of CyclinD1, MMP2 and TIMP1 mRNA in NIH3T3 cells was detected by RT-PCR. The expression of CyclinD1, MMP2 and TIMP1 protein and the level of MYPT1 phosphorylation in NIH3T3 cells was detected by Western blot.
  
  
  RESULTS
  Compare to the mice administrated by bleomycin, the Ashcroft score and hydroxyproline content were significantly decreased in the mice administered fasudil. Administration of fasudil can reduce the ability of proliferation and migration in a dose-dependent manner in NIH3T3 cells. The effect of fasudil was possibly related to increase the production of TIMP1 and decrease the production of CyclinD1 and MMP2.
  
  
  CONCLUSIONS
  Administration of fasudil can attenuate pulmonary fibrosis both in vivo and in vitro. These findings suggest that fasudil may be a potential therapeutic candidate for the treatment of pulmonary fibrosis.
authors.affiliation: Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
authors.forename: Chunguo
authors.initials: C
authors.lastname: Jiang
authors.forename: Hui
authors.initials: H
authors.lastname: Huang
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.forename: Yanxun
authors.initials: Y
authors.lastname: Wang
authors.forename: Yuyue
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Email: xuzj@hotmail.com.
authors.forename: Zuojun
authors.initials: Z
authors.lastname: Xu
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001761:Bleomycin / Q000009:adverse effects; D019938:Cyclin D1 / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects; D008168:Lung / Q000473:pathology; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D051379:Mice; D041681:NIH 3T3 Cells; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism
chemical_list: C530105:Ccnd1 protein, mouse; C560825:Timp1 protein, mouse; D019715:Tissue Inhibitor of Metalloproteinase-1; D001761:Bleomycin; D019938:Cyclin D1; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D020778:Matrix Metalloproteinase 2; C522362:Mmp2 protein, mouse; C049347:fasudil